Real-world performance of the MiniMed™ 670G system in Europe

Julien Da Silva, Emanuele Bosi, Johan Jendle, Arcelia Arrieta, Javier Castaneda, Benyamin Grossman, Toni L. Cordero*, John Shin, Ohad Cohen

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

42 Scopus citations

Abstract

Aim: To evaluate the real-world performance of the MiniMed 670G system in Europe, in individuals with diabetes. Materials and Methods: Data uploaded from October 2018 to July 2020 by individuals living in Europe were aggregated and retrospectively analysed. The mean glucose management indicator (GMI), percentage of time spent within (TIR), below (TBR) and above (TAR) glycaemic ranges, system use and insulin consumed in users with 10 or more days of sensor glucose data after initial Auto Mode start were determined. Another analysis based on suboptimally (GMI > 8.0%) and well-controlled (GMI < 7.0%) glycaemia pre-Auto Mode initiation was also performed. Results: Users (N = 14 899) spent a mean of 81.4% of the time in Auto Mode and achieved a mean GMI of 7.0% ± 0.4%, TIR of 72.0% ± 9.7%, TBR less than 3.9 mmol/L of 2.4% ± 2.1% and TAR more than 10 mmol/L of 25.7% ± 10%, after initiating Auto Mode. When compared with pre-Auto Mode initiation, GMI was reduced by 0.3% ± 0.4% and TIR increased by 9.6% ± 9.9% (P <.0001 for both). Significantly improved glycaemic control was observed irrespective of pre-Auto Mode GMI levels of less than 7.0% or of more than 8.0%. While the total daily dose of insulin increased for both groups, a greater increase was observed in the latter, an increase primarily due to increased basal insulin delivery. By contrast, basal insulin decreased slightly in well-controlled users. Conclusions: Most MiniMed 670G system users in Europe achieved TIR more than 70% and GMI less than 7% while minimizing hypoglycaemia, in a real-world environment. These international consensus-met outcomes were enabled by automated insulin delivery meeting real-time insulin requirements adapted to each individual user.

Original languageEnglish
Pages (from-to)1942-1949
Number of pages8
JournalDiabetes, Obesity and Metabolism
Volume23
Issue number8
DOIs
StatePublished - Aug 2021
Externally publishedYes

Funding

FundersFunder number
Medtronic International Trading Sàrl

    Keywords

    • closed-loop system
    • diabetes
    • glucose management indicator
    • hyperglycaemia
    • hypoglycaemia
    • real-world evidence
    • time in range

    Fingerprint

    Dive into the research topics of 'Real-world performance of the MiniMed™ 670G system in Europe'. Together they form a unique fingerprint.

    Cite this